Mazzilli, Sarah A;
Rahal, Zahraa;
Rouhani, Maral J;
Janes, Sam M;
Kadara, Humam;
Dubinett, Steven M;
Spira, Avrum E;
(2025)
Translating premalignant biology to accelerate non-small-cell lung cancer interception.
Nature Reviews Cancer
, 25
pp. 379-392.
10.1038/s41568-025-00791-1.
Preview |
Text
Janes_1. NRC-20-167 Spira_final 07302024.pdf Download (1MB) | Preview |
Abstract
Over the past decade, substantial progress has been made in the development of targeted and immune-based therapies for patients with advanced non-small-cell lung cancer. To further improve outcomes for patients with lung cancer, identifying and intercepting disease at the earliest and most curable stages are crucial next steps. With the recent implementation of low-dose computed tomography scan screening in populations at high risk, there is an emerging unmet need for new diagnostic, prognostic and therapeutic tools to help treat patients suspected of harbouring premalignant lesions and minimally invasive non-small-cell lung cancer. Continued advances in the identification of the earliest drivers of lung carcinogenesis are poised to address these unmet needs. Employing multimodal approaches to chart the temporal and spatial maps of the molecular events driving lung premalignant lesion progression will refine our understanding of early carcinogenesis. Elucidating the molecular drivers of premalignancy is critical to the development of biomarkers to detect those incubating a premalignant lesion, to stratify risk for progression to invasive cancer and to identify novel therapeutic targets to intercept that process. In this Review, we summarize emerging insights into the earliest cellular and molecular events associated with lung squamous and adenocarcinoma carcinogenesis and highlight the growing opportunity for translating these insights into clinical tools for early detection and disease interception to transform the outcomes for those at risk for lung cancer.
Archive Staff Only
 |
View Item |
